![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
![[thumbnail of 11304oa.pdf]](https://mdc-test.eprints-hosting.org/style/images/fileicons/application_pdf.png) |
PDF
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
197kB |
| Item Type: | Article |
|---|---|
| Title: | Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia |
| Creators Name: | Kim, T.D., Schwarz, M., Nogai, H., Grille, P., Westermann, J., Ploeckinger, U., Braun, D., Schweizer, U., Arnold, R., Doerken, B. and le Coutre, P. |
| Abstract: | BACKGROUND: Thyroid dysfunction is a well-known adverse effect of first-generation tyrosine kinase inhibitors (TKIs), like sunitinib. The aim of this study was to investigate the effect of second-generation TKIs on thyroid function. METHODS: We retrospectively assessed the effect of the first-generation TKI imatinib and the second-generation TKI nilotinib and dasatinib on thyroid function tests in 73 Philadelphia chromosome-positive (Ph-positive) chronic myeloid leukemia patients. RESULTS: Overall, 33 of 73 (45%) had one or more thyroid function test abnormalities during follow-up. Hypothyroidism or hyperthyroidism were found in 18 of 73 (25%) and 21 of 73 (29%) cases after a median of 6 and 22 weeks, respectively. In most patients (29 of 39, 74%) thyroid dysfunction was transient without clinical symptoms. Therapy of hypo-/hyperthyroidism was required in three patients. Thyroid dysfunction never resulted in the discontinuation of TKI therapy. Under treatment with imatinib, nilotinib, and dasatinib, thyroid abnormalities were detected in 25%, 55%, and 70%, respectively. Four of 55 patients (7%) treated with nilotinib had evidence for an autoimmune thyroiditis (antibody positive in 3 of 4 patients) with an episode of hyperthyroidism preceding hypothyroidism. CONCLUSIONS: Thyroid dysfunction is a common adverse event with second-generation TKI therapy in patients with Ph-positive chronic myeloid leukemia. Although the mechanism is still unclear, the high frequency of thyroid abnormalities, including autoimmune thyroiditis, warrants regular and long-term monitoring of thyroid function in these patients. |
| Keywords: | Antineoplastic Agents, BCR-ABL Positive Chronic Myelogenous Leukemia, Philadelphia Chromosome, Piperazines, Protein Kinase Inhibitors, Pyrimidines, Retrospective Studies, Thiazoles, Thyroid Diseases, Thyroid Function Tests, Thyroid Gland |
| Source: | Thyroid |
| ISSN: | 1050-7256 |
| Publisher: | Mary Ann Liebert |
| Volume: | 20 |
| Number: | 11 |
| Page Range: | 1209-1214 |
| Date: | 9 November 2010 |
| Official Publication: | https://doi.org/10.1089/thy.2010.0251 |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
